33 patents currently held
1 more in force is now held by another company
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Dec 2037. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Dec 2037
Next term end
22
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Dec 2038 · High confidence
Also notable
Ends Aug 2038 · High confidence
Also notable
Ends Jun 2039 · High confidence
BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR EphA2
US 11,484,602
Cited by 33 later US patents, top 5% of utility patents granted in 2022 in our data. Protection runs to 2038. A terminal disclaimer caps this term to an earlier patent's.
Bicyclic Peptide Ligand Specific for CD137
US 11,261,214
Cited by 29 later US patents, top 5% of utility patents granted in 2022 in our data. Protection runs to 2038.
Bicyclic Peptide Ligands Specific for NECTIN-4
US 11,180,531
Cited by 34 later US patents, top 5% of utility patents granted in 2021 in our data. Protection runs to 2039.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jan 11, 2027The maintenance fee for Bicyclic Peptide Ligands Specific for EPHA2 (US 11,696,956) comes due Jan 11, 2027. Unpaid by Jul 12, 2027, it lapses early.
- 1 fee due Feb 22, 2027The maintenance fee for Peptide Derivatives Having Novel Linkage Structures (US 11,730,819) comes due Feb 22, 2027. Unpaid by Aug 23, 2027, it lapses early.
- 1 fee due Jun 5, 2027The maintenance fee for Methods of Suppression and Treatment of Disease Comprising administering Bicycle Peptide Ligands Specific for EphA2 (US 11,833,211) comes due Jun 5, 2027. Unpaid by Dec 6, 2027, it lapses early.
- 2 fees due Aug 20 to 27, 2027 · next Aug 20
- 2 fees due Oct 30, 2027
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
What they patent
The 5 largest of its 22 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Heterotandem Bicyclic Peptide Complex (2020) | 3 in force | to Jul 2040 |
| Bicyclic Peptide Ligands Specific for NECTIN-4 | 3 in force | to Jun 2039 |
| Multimeric Bicyclic Peptide Ligands | 3 in force | to Feb 2039 |
| Bicyclic Peptide Ligand Specific for CD137 | 3 in force | to Aug 2038 |
| Heterotandem Bicyclic Peptide Complex (2020) | 2 in force | to Jul 2040 |
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,730,819 | Peptide Derivatives Having Novel Linkage Structures In force · Medium confidence | In force | Medium confidence | |
| US 11,433,137 | Compounds for Treating Cancer In force · High confidence | In force | High confidence | |
| US 10,857,196 | Bicyclic Peptide Ligands and Uses Thereof In force · High confidence | In force | High confidence | |
| US 11,261,214 | Bicyclic Peptide Ligand Specific for CD137 In force · High confidence | In force | High confidence | |
| US 12,049,520 | Bicyclic Peptide Ligands Specific for CD137 In force · Medium confidence | In force | Medium confidence | |
| US 12,630,588 | Bicyclic Peptide Ligands Specific for CD137 In force · Low confidence | In force | Low confidence | |
| US 11,484,602 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR EphA2 In force · High confidence | In force | High confidence | |
| US 11,696,956 | Bicyclic Peptide Ligands Specific for EPHA2 In force · High confidence | In force | High confidence | |
| US 11,833,211 | Methods of Suppression and Treatment of Disease Comprising administering Bicycle Peptide Ligands Specific for EphA2 In force · High confidence | In force | High confidence | |
| US 10,875,894 | Multimeric Bicyclic Peptide Ligands In force · High confidence | In force | High confidence |
Also on record, not counted in the 33: 1 patent in force now held by others · 3 patents ended · 36 applications pending · 27 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.